|
Radium-223 treatment patterns in a large real-world population. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Janssen |
|
|
Stock and Other Ownership Interests - SNP Bio |
|
|
|
Consulting or Advisory Role - Astellas Pharma; Dendreon; MDxHealth; Myriad Pharmaceuticals; Steba Biotech |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Genomic Health (I) |
Stock and Other Ownership Interests - Armune Bioscience |
Consulting or Advisory Role - Ache; Astellas Pharma; AstraZeneca; Bayer; Dendreon; Ferring; Janssen Biotech; Pfizer |
Research Funding - Bayer (Inst); Diasorin; GenomeDx (Inst); Janssen Biotech (Inst); MDxHealth (Inst); Myriad Genetics (Inst); OPKO Diagnostics (Inst); Progenika (Inst) |
Travel, Accommodations, Expenses - Sanofi |